{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:36:27Z","timestamp":1760243787091,"version":"build-2065373602"},"reference-count":33,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2012,11,8]],"date-time":"2012-11-08T00:00:00Z","timestamp":1352332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an extremely rare syndrome with autosomal dominant inheritance. HLRCC is characterized by a predisposition to leiomyomas of the skin and the uterus as well as renal cell carcinoma. The disease-related gene has been identified as fumarate hydratase (fumarase, FH), which encodes an enzyme involved in the mitochondrial tricarboxylic acid cycle. Protein profiling may give some insight into the molecular pathways of HLRCC. Therefore, we performed protein profiling of blood samples from HLRCC patients, their family members, and healthy volunteers, using surface-enhanced laser desorption\/ionization time-of-flight mass spectrometry (SELDI-TOF MS) coupled with IMAC-Cu chips. For hierarchical clustering analysis, we used the 45 peaks that revealed significant differences in single-marker analysis over the range from 1500 to 15,000 m\/z. Heat map analysis based on the results of clustering distinguished the HLRCC kindred from non-HLRCC subjects with a sensitivity of 94% and a specificity of 90%. SELDI-TOF MS profiling of blood samples can be applied to identify patients with HLRCC and to assess specific molecular mechanisms involved in this condition.<\/jats:p>","DOI":"10.3390\/ijms131114518","type":"journal-article","created":{"date-parts":[[2012,11,8]],"date-time":"2012-11-08T11:04:29Z","timestamp":1352372669000},"page":"14518-14532","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Protein Profiling of Blood Samples from Patients with Hereditary Leiomyomatosis and Renal Cell Cancer by Surface-Enhanced Laser Desorption\/Ionization Time-of-Flight Mass Spectrometry"],"prefix":"10.3390","volume":"13","author":[{"given":"Takao","family":"Kamai","sequence":"first","affiliation":[{"name":"Department of Urology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohisa","family":"Tomosugi","sequence":"additional","affiliation":[{"name":"Proteomics Research Unit, Division of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa 920-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Urology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Kaji","sequence":"additional","affiliation":[{"name":"Department of Radiology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsunari","family":"Oyama","sequence":"additional","affiliation":[{"name":"Department of Pathology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-Ichiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Urology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2012,11,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1073\/pnas.051633798","article-title":"Inherited susceptibility to uterine leiomyomatosis and renal cell cancer","volume":"98","author":"Launonen","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0002-9440(10)61757-9","article-title":"Inherited familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology","volume":"159","author":"Kiuru","year":"2001","journal-title":"Am. J. Pathol"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/hmg\/ddg148","article-title":"Genetic and functional analyses of FH mutations in multiple cutaneous and uterin leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency","volume":"12","author":"Alam","year":"2003","journal-title":"Hum. Mol. Geet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.juro.2007.01.155","article-title":"Hereditary leiomyomatosis and renal cell cancer: A syndrome associated with an aggressive form of inherited renal cancer","volume":"177","author":"Grubb","year":"2007","journal-title":"J. Urol"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat. Genet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2133.2005.06678.x","article-title":"Inherited fumarate hydratase mutations and predisposition to cutaneous leiomyomas, uterine leiomyomas and renal cancer","volume":"153","author":"Alam","year":"2005","journal-title":"Br. J. Dermatol"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrc1041","article-title":"The case for early detection","volume":"3","author":"Etzioni","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nature01511","article-title":"Mass spectrometry-based proteomics","volume":"422","author":"Aebersold","year":"2003","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"671s","DOI":"10.1158\/1078-0432.CCR-06-1870","article-title":"Identification of the genes for kidney cancer: Opportunity for disease specific targeted therapeutics","volume":"13","author":"Linehan","year":"2007","journal-title":"Clin. Cancer Res"},{"key":"ref_10","first-page":"4554","article-title":"Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families","volume":"62","author":"Kiuru","year":"2002","journal-title":"Cancer Res"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/PAS.0b013e31804375b8","article-title":"The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome","volume":"31","author":"Merino","year":"2007","journal-title":"Am. J. Sur. Pathol"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ncpuro0711","article-title":"Mechanisms of disease: Hereditary leiomyomatosis and renal cell cancer\u2014A distinct form of hereditary kidney cancer","volume":"4","author":"Sudarshan","year":"2007","journal-title":"Nat. Clin. Pract. Urol"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/sj.bjc.6603547","article-title":"HIF and fumarate hydratase in renal cancer","volume":"96","author":"Sudarshan","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/hmg\/ddi227","article-title":"Accumulation of Krebs cycle intermediates and over-expression of HIF1 in tumours which result from germline FH and SDH mutations","volume":"14","author":"Pollard","year":"2005","journal-title":"Hum. Mol. Genet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","article-title":"HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability","volume":"8","author":"Isaacs","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(02)00071-5","article-title":"HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron","volume":"1","author":"Mandriota","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2007.02.005","article-title":"Targeted inactivation of Fh1 causes prolirerative renal cyst development and activation of the hypoxia pathway","volume":"11","author":"Pollard","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2011.09.006","article-title":"Renal cyst formation in Fh-1-Deficient mice is independent of the Hif\/Phd pathway: Roles for fumarate in KEAP1 succination and Nrf2 signaling","volume":"20","author":"Adam","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1000328","DOI":"10.1371\/journal.pbio.1000328","article-title":"Fumarase: A mitochondrial metabolic enzyme and a cytosolic\/nuclear component of NA damage response","volume":"8","author":"Yogev","year":"2010","journal-title":"PLoS Biol"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nature10363","article-title":"Heam oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase","volume":"477","author":"Frezza","year":"2011","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bbadis.2008.01.008","article-title":"Differential metabolic consequences of fumarate hydratase and respiratory chain defects","volume":"1782","author":"Raimundo","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/onc.2008.472","article-title":"Downregulation of SRF-FOS-JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas","volume":"28","author":"Raimundo","year":"2009","journal-title":"Oncogene"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00109-011-0728-4","article-title":"Inborn and acquired metabolic defects in cancer","volume":"89","author":"Frezza","year":"2011","journal-title":"J. Mol. Med"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.molmed.2011.06.001","article-title":"Revisiting the TCA cycle: Signaling to tumor formation","volume":"11","author":"Raimundo","year":"2011","journal-title":"Trends Mol. Med"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1086\/376435","article-title":"Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America","volume":"73","author":"Toro","year":"2003","journal-title":"Am. J. Hum. Genet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(02)07746-2","article-title":"Use of proteomic patterns in serum to identify ovarian cancer","volume":"359","author":"Petricoin","year":"2002","journal-title":"Lancet"},{"key":"ref_27","first-page":"149A","article-title":"SELDI-TOF MS for diagnostic proteomics","volume":"75","author":"Isaaq","year":"2003","journal-title":"Anal. Chem"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/1078-0432.963.11.3","article-title":"Plasma protein profiling by mass spectrometry for cancer diagnosis: Opportunities and limitations","volume":"11","author":"Diamandis","year":"2005","journal-title":"Clin. Cancer Res"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.tips.2006.03.003","article-title":"Clinical proteomics: Searching for better tumour markers with SELDI-TOF mass spectrometry","volume":"27","author":"Engwegen","year":"2006","journal-title":"Trends Pharmacol. Sci"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0378-4274(01)00269-7","article-title":"Proteomic profiling from human samples: The body fluid alternative","volume":"120","author":"Kennedy","year":"2001","journal-title":"Toxicol. Lett"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1586\/14789450.4.3.401","article-title":"Oncoproteomics: Current trends and future perspectives","volume":"4","author":"Cho","year":"2007","journal-title":"Expert Rev. Proteomics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/sj.bjc.6605700","article-title":"Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis","volume":"102","author":"Cho","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_33","first-page":"73","article-title":"Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption\/ionization time-of-flight mass spectrometry to discriminate between prostate cancer and benign lesions","volume":"21","author":"Okamoto","year":"2009","journal-title":"Oncol Rep"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/13\/11\/14518\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:53:26Z","timestamp":1760219606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/13\/11\/14518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,8]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11]]}},"alternative-id":["ijms131114518"],"URL":"https:\/\/doi.org\/10.3390\/ijms131114518","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2012,11,8]]}}}